市場調査レポート
商品コード
1462314
SUNOSI市場:市場規模、予測、市場洞察-2032年SUNOSI Market Size, Forecast, and Market Insight - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
SUNOSI市場:市場規模、予測、市場洞察-2032年 |
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
SUNOSIはドパミン・ノルエピネフリン再取り込み阻害薬(DNRI)であり、ナルコレプシーまたはOSAによるEDSを有する成人の覚醒改善を適応としています。2014年、Jazz PharmaceuticalsはAerial BiopharmaからSUNOSIの開発・商業化ライセンスを取得しました。Jazz Pharmaceuticalsは、アジアの一部の地域を除き、SUNOSIの全世界における開発、製造、商業化の権利を有しています。本化合物の発見者であるSK Biopharmaceuticalsは、韓国、中国、日本を含む12のアジア市場における権利を保持しています。
今後数年間で、閉塞性睡眠時無呼吸症候群(OSA)の市場シナリオは、世界中の広範な調査と医療支出の増加により変化します。各社は、病状を治療/改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、SUNOSIの優位性に影響を与える可能性のある機会を模索しています。他のOSA治療薬もSUNOSIと厳しい市場競争を繰り広げることが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。
当レポートでは、主要6ヶ国における閉塞性睡眠時無呼吸症候群(OSA)治療薬のSUNOSI市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。
"SUNOSI Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about SUNOSI for Obstructive sleep apnea (OSA) in the six major markets. A detailed picture of the SUNOSI for OSA in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom for the study period 2019 -2032 is provided in this report along with a detailed description of the SUNOSI for OSA. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SUNOSI market forecast analysis for OSA in the 6MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in OSA.
SUNOSI is a dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) and is indicated to improve wakefulness in adults living with EDS due to narcolepsy or OSA. In 2014, Jazz Pharmaceuticals acquired a license to develop and commercialize SUNOSI from Aerial Biopharma. Jazz Pharmaceuticals has worldwide development, manufacturing, and commercialization rights to SUNOSI, excluding certain jurisdictions in Asia. SK Biopharmaceuticals, the discoverer of the compound, maintains rights in 12 Asian markets, including Korea, China, and Japan.
Dosage
Mechanism of action
The mechanism of action of solriamfetol to improve wakefulness in patients with EDS associated with narcolepsy or OSA is unclear. However, its efficacy could be mediated through its activity as a dopamine and norepinephrine reuptake inhibitor (DNRI).
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
SUNOSI Analytical Perspective by DelveInsight
This report provides a detailed market assessment of SUNOSI for Obstructive sleep apnea (OSA) in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom. This segment of the report provides forecasted sales data from 2024 to 2032.
The report provides the clinical trials information of SUNOSI for OSA covering trial interventions, trial conditions, trial status, start and completion dates.